Authors: Tokioka-Akagi, T Fujimori, A Shibasaki, M Inagaki, O Yanagisawa, I

Citation: T. Tokioka-akagi et al., Comparison of the angiotensin II type 1-receptor antagonist YM358 and the angiotensin-converting enzyme inhibitor enalapril in rats with cardiac volume overload, JPN J PHARM, 86(1), 2001, pp. 79-85

Authors: Ohmi, N Wingfield, JM Yazawa, H Inagaki, O

Citation: N. Ohmi et al., Development of a homogeneous time-resolved fluorescence assay for high throughput screening to identify Lck inhibitors: Comparison with scintillationproximity assay and streptavidin-coated plate assay, J BIOMOL SC, 5(6), 2000, pp. 463-470

Authors: Tokioka, T Shibasaki, M Fujimori, A Matsuda-Satoh, Y Uchida, W Inagaki, O Yanagisawa, I

Citation: T. Tokioka et al., Effects of YM358, an angiotensin II type 1 (AT(1)) receptor antagonist, and enalapril on blood pressure and vasoconstriction in two renal hypertension models, BIOL PHAR B, 23(2), 2000, pp. 174-181

Authors: Inagaki, O Asano, M Takenaka, T

Citation: O. Inagaki et al., In vitro and in vivo vasodilatory activity of barnidipine and its enantiomers, BIOL PHAR B, 22(2), 1999, pp. 151-156

Authors: Sakai, T Inagaki, O Teshima, T

Citation: T. Sakai et al., Analysis of neutrino oscillation in three-flavor neutrinos, INT J MOD P, 14(12), 1999, pp. 1953-1974

Authors: Yatsu, T Tomura, Y Tahara, A Wada, K Kusayama, T Tsukada, J Tokioka, T Uchida, W Inagaki, O Iizumi, Y Tanaka, A Honda, K

Citation: T. Yatsu et al., Cardiovascular and renal effects of conivaptan hydrochloride (YM087), a vasopressin V-1A and V-2 receptor antagonist, in dogs with pacing-induced congestive heart failure, EUR J PHARM, 376(3), 1999, pp. 239-246